Riemser Arzneimittel AG Sells Veterinary Business to Ecuphar N.V.

Riemser Arzneimittel AG Sells Veterinary Business to Ecuphar N.V.

Greifswald - Isle of Riems, Germany and Oostkamp, Belgium, March 2, 2011 / b3c newswire / - Riemser Arzneimittel AG and Belgian company Ecuphar N.V. have announced that they have agreed on the sale of a large part of the veterinary business of Riemser to Ecuphar. The sale should take place during the first quarter of 2011.


As part of its further strategic development as a specialty pharmaceutical supplier, Riemser Arzneimittel AG will be selling a large part of both its veterinary product portfolio and its marketing and sales unit, to Ecuphar. The research and development and production divisions, as well as the Riemser swine flu will remain at Riemser. This acquisition will grant the Belgian company Ecuphar, which is specialised in veterinary medicine, direct access to the German veterinary market, an important factor in its European expansion strategy. In the future, Ecuphar will operate in Germany under the name of Ecuphar GmbH. The Company will be located in Greifswald.


"With Ecuphar, we are pleased to have found a partner who will continue and successfully expand the veterinary business we have built up. Riemser will thus be able to focus even more intensely on further growth in the area of human specialty pharmaceuticals", explains Dr. Michael Mehler, Chairman of the board of Riemser.


"The acquisition of the veterinary portfolio from Riemser, together with the experienced marketing and sales team is a stroke of luck for us, as it will allow us to gain quick, direct access to the German market. The acquired products will also complement our existing portfolio, with the result that we expect our position in the German market to be reinforced", comments Chris Cardon, CEO of Ecuphar N.V..


Both companies will also continue to cooperate following the sale. Ecuphar will continue to receive the products manufactured by Riemser in Greifswald and Leipzig exclusively from Riemser. "The production agreement is a job security measure for our locations and as such a significant part of the selling process", adds Dr. Mehler.



About RIEMSER Arzneimittel AG - www.RIEMSER.com

A company with a tradition and a future: RIEMSER Arzneimittel AG is a specialised, internationally active mid-sized pharmaceutical company which produces and markets human therapeutic agents. In recent years, RIEMSER Arzneimittel AG has been among the fastest growing pharmaceutical companies within Germany. Its main headquarters are in Greifswald (Germany).


The product range of RIEMSER AG in the human field particularly includes prescription medications against skin and infectious disorders, particularly tuberculosis, cancer therapy agents for supportive and palliative care as well as cardiovascular products. In the field of dental medicine, it focuses on bone regeneration with tooth preservation and replacement as well as on an innovative implant system. The portfolio is complemented by products for pain relief and inflammation treatment in cases of dental inflammation.


About Ecuphar - www.ecuphar.com

Ecuphar's primary business is the development and marketing of a broad range of veterinary products and services.  Well-known trademarks on the German market are Enurace® (incontinence for dogs), Orozyme® (oral hygiene for cats and dogs) and Dermazyme® (dermatology for cats and dogs). ECUPHAR has several subsidiaries and business units that are involved in different activities within the animal health industry. The company has a consolidated turnover of over € 34 million and a solid financial structure with Equity of over € 16 million.



Herrn Jeroen Bastijns
Legeweg 157i
8020 Oostkamp, Belgien
Tel.: +32 50 314 510
Fax: +32 50 545 067
[email protected] e-mail address is being protected from spambots. You need JavaScript enabled to view it

RIEMSER Arzneimittel AG
Frau Franziska Hannemann
An der Wiek 7
17493 Greifswald-Insel Riems
Tel.: +49 3851-76-129
Fax: +49 3851-7648
[email protected] e-mail address is being protected from spambots. You need JavaScript enabled to view it